Prognostic Value of Oral Epstein–Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma
-
Published:2022-01-13
Issue:
Volume:8
Page:
-
ISSN:2296-889X
-
Container-title:Frontiers in Molecular Biosciences
-
language:
-
Short-container-title:Front. Mol. Biosci.
Author:
He Yong-Qiao,Zhou Ting,Yang Da-Wei,Jia Yi-Jing,Yuan Lei-Lei,Zhang Wen-Li,Wang Tong-Min,Liao Ying,Xue Wen-Qiong,Zhang Jiang-Bo,Zheng Xiao-Hui,Li Xi-Zhao,Zhang Pei-Fen,Zhang Shao-Dan,Hu Ye-Zhu,Wang Fang,Cho William C.,Ma Jun,Sun Ying,Jia Wei-Hua
Abstract
Background: Plasma Epstein–Barr virus (EBV) DNA load has been widely used for nasopharyngeal carcinoma (NPC) prognostic risk stratification. However, oral EBV DNA load, a non-invasive biomarker that reflects the EBV lytic replication activity, has not been evaluated for its prognostic value in NPC yet.Methods: A total number of 1,194 locoregionally advanced NPC (LA-NPC) patients from south China were included from a prospective observational cohort (GARTC) with a median follow-up of 107.3 months. Pretreatment or mid-treatment mouthwashes were collected for EBV DNA detection by quantitative polymerase chain reaction (qPCR). The difference of pre- and mid-treatment oral EBV DNA load was tested by the Wilcoxon signed-rank test. The associations of oral EBV DNA load with overall survival (OS), progression-free survival (PFS), distant metastasis–free survival (DMFS), and locoregional relapse-free survival (LRFS) were assessed using the log-rank test and multivariate Cox regression.Results: The high level of the oral EBV DNA load (>2,100 copies/mL) was independently associated with worse OS (HR = 1.45, 95% CI: 1.20–1.74, p < 0.001), PFS (HR = 1.38, 95% CI: 1.16–1.65, p < 0.001), DMFS (HR = 1.66, 95% CI: 1.25–2.21, p = 0.001), and LRFS (HR = 1.43, 95% CI: 1.05–1.96, p = 0.023). Similar and robust associations between oral EBV DNA load and prognosis were observed for patients in both the pretreatment and mid-treatment stages. The detection rate (71.7 vs. 48.6%, p < 0.001) and the median load of oral EBV DNA (13,368 vs. 382 copies/mL, p < 0.001) for patients in the pretreatment stage were significantly higher than those in the mid-treatment stage. The combination of the oral EBV DNA load and TNM staging provided a more precise risk stratification for the LA-NPC patients.Conclusion: Oral EBV DNA load was an alternative non-invasive predictor of prognosis and may facilitate risk stratification for the LA-NPC patients.
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research
National Science Fund for Distinguished Young Scholars
Fundamental Research Funds for the Central Universities
Natural Science Foundation of Guangdong Province
Science and Technology Planning Project of Guangdong Province
Special Project for Research and Development in Key Areas of Guangdong Province
Publisher
Frontiers Media SA
Subject
Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献